XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | $13,663 | $13,079 | $11,771 | $16,403 |
| - Cash | $371 | $820 | $594 | $1,068 |
| + Debt | $138 | $168 | $0 | $0 |
| Enterprise Value | $13,430 | $12,427 | $11,177 | $15,335 |
| Revenue | $289 | $162 | $0 | $0 |
| % Growth | 78.4% | – | – | – |
| Gross Profit | -$43 | $162 | $0 | $0 |
| % Margin | -14.9% | 100% | – | – |
| EBITDA | -$429 | -$156 | -$691 | $485 |
| % Margin | -148.5% | -96.3% | – | – |
| Net Income | -$255 | -$553 | -$704 | $485 |
| % Margin | -88.2% | -341.4% | – | – |
| EPS Diluted | -0.04 | -0.1 | -0.13 | 0.09 |
| % Growth | 60% | 23.1% | -244.4% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |